Autoimmune & Inflammatory Immunomodulators Market Research Report covers the present scenario and the growth prospects of the Autoimmune & Inflammatory Immunomodulators Industry for 2016-2020. Autoimmune & Inflammatory Immunomodulators Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Autoimmune & Inflammatory Immunomodulators globally.
For further information on this report, please visit- http://www.marketreportsworld.com/10289427
The Autoimmune & Inflammatory Immunomodulators report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Autoimmune & Inflammatory Immunomodulators Market:
- Johnson & Johnson
- F. Hoffmann-La Roche
Other Prominent Vendors of Autoimmune & Inflammatory Immunomodulators Market Are:
- Avaxia Biologics
- Biogen Idec
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Eli Lilly
- Enlivex Therapeutics
- Gilead Sciences
“One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future.”
Ask Sample PDF of Autoimmune & Inflammatory Immunomodulators Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10289427
According to the Autoimmune & Inflammatory Immunomodulators report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie’s Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY). The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn’s disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies).
Report also presents Geographical Segmentation analysis of Autoimmune & Inflammatory Immunomodulators Market of Americas, APAC, EMEA region.
For Any Query, Contact Our Expert @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10289427
Further, the Autoimmune & Inflammatory Immunomodulators report states that one major challenge in the market is discontinuation of drugs under development leading to substantial loss of revenue. Discontinuation of the drugs under development or from the market after its launch due to non-satisfactory safety or efficacy result is a major challenge for the market. Discontinuation in the late stages of development or from the market will lead to a heavy loss in revenues because of the high R&D and marketing costs invested by the company. Discontinuation of rheumatoid arthritis and IBD drugs is high as the drug target is not properly understood before the drug trial commences. Also, the drugs are sometimes discontinued at the later stages of the trial as unacceptable adverse effects appear on the body.
Key questions answered in Autoimmune & Inflammatory Immunomodulators market report:
- What will the Autoimmune & Inflammatory Immunomodulators market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving Autoimmune & Inflammatory Immunomodulators market?
- What are the challenges to Autoimmune & Inflammatory Immunomodulators market growth?
- Who are the key vendors in Autoimmune & Inflammatory Immunomodulators market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No of Pages: 98
Price of Report: $ 2500 (Single User License)
Purchase Report @ http://www.marketreportsworld.com/purchase/10289427
About Market Reports World:
Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Mr. Ameya Pingaley
Market Reports World
+1 408 520 9750
Email – firstname.lastname@example.org